Attendee search 

Corporate Venture Capital function for PTT Global Chemical, the biggest polyolefin manufacturer in Southeast Asia.

Located at the High-Tech center, Silicon Valley, ZJ Future was established in 2013 as a bridge between China and the US to offer accelerating services for domestic enterprises with global perspectives. ​



With the vision of accelerating enterprise development and growth, we leverage the complementary advantages of North America, Europe, South America, and the Asia-Pacific regions to connect high-quality projects with industry leaders, promote academic communications and interactions in high-tech fields, aggregate global entrepreneurial and innovative resources, build an effective and efficient global innovation ecosystem, and develop high-level and multi-field cooperation in the fields of economy, trade, investment, science, and technology.

Located in Jinan, Qilu Pharmaceutical is one of the leading pharmaceutical companies in China. It focuses on developing, manufacturing and marketing of generic drugs and active pharmaceutical ingredients in the therapeutic areas of Oncology, Cerebrovascular & Cardiovascular, Infections, Psychological&Neurological System, Respiratory System, Ophthalmological Diseases, etc. Qilu has more than 8000 employees, 70% of which have the college degree or above.

Qilu pharmaceutical has always been sticking to the innovative development strategy. Guided by the market demand and the product innovation, Qilu has established extensive cooperation with domestic and foreign partners on a series of R&D projects. Qilu pays high attention to the introduction and cultivation of talents and has built a highly qualified R&D team with professional and efficient R&D capabilities, More than 100 national new drugs have been successfully developed, which constitutes the reasonable production line for the future development of Qilu. A number of technological achievements have obtained the national and provincial scientific & technological progress awards and created good social benefit.

Qilu Pharmaceutical has eight manufacturing sites covering an area of more than 2800,000 ㎡for finished dosage forms, chemical synthesis, genetic-engineering, fermentation, etc. The modern workshops are located in the manufacturing sites where the automatic production lines, key equipments and analytical instruments are imported from the leading suppliers all over the world. Now Qilu Pharmaceutical has been one of the leading global suppliers of Antibiotic APIs and Oncology APIs with huge capacity and good quality.

Qilu pharmaceutical has always been committing itself to providing the high-quality products to the patients and the society. Thanks to the integrated and stringent system of quality control and quality assurance, the company has been the leader of cGMP implementation in China. Its non-sterile APIs (fermentation and chemical synthesis), sterile APIs and comprehensive finished dosages have been respectively approved by USFDA, European Directorate for the Quality of Medicines (EDQM), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, Medicines Control Council (MCC) of South Africa, and some other national competent authorities.

Qilu Pharmaceutical has an integrated product structure and value chain with over 160 launched products. The company has established a comprehensive domestic and overseas sales network. The global presence has covered North America, Europe, CIS countries, South America, Asia, South Africa and Middle East. The valuable brand of the company has been well built with the quality products and good services.

We are a group of angels selecting top companies to invest.

Big Pharma

华润集团一级利润中心，聚焦生命科学领域投资与合作

Approximately 900,000 people annually in the United States suffer from damage to the articular cartilage and subchondral bone, with the knee being the most commonly affected. Articular cartilage lesions have a limited intrinsic ability to heal and often result in osteoarthritis (OA). Progression to OA poses significant economic burden for the United States, totaling over $300 billion annually, and negatively impacting 54.4 million adults (23% of the population). Current strategies for cartilage restoration include bone marrow stimulation (microfracture) and autologous chondrocyte implantation (ACI). These methods have high failure rates (25-50% at 10 years), prolonged rehabilitation times (> 12 months), and show decreasing efficacy in patients older than 40-50 years of age. 

Sparta Biomedical is developing the first-of-its kind osteochondral repair technology (SBM-01) for support the restoration of the cartilage-bone unit. This purpose-built technology is comprised of a novel biomimetic material possesses cartilage-like properties-- tension, compression, tribology, and fatigue.  The patent-pending surface is combined with a uniquely designed base to promote efficient osseous attachment and stable fixation over the long-term. Sparta’s technology will be a significant advancement in the current surgical standard of care. It will result in substantial pain reduction, immediate weight bearing post-operatively, and full range ambulation.

Sparta has assembled a nationally recognized team of scientists, clinicians, orthopedic regulatory experts to develop SBM-01 rapidly and cost effectively. SBM-01's risk profile enables an efficient regulatory path. Furthermore, it is well positioned to obtain Breakthrough Device Designation from the US FDA.